- $167.80bn
- $219.60bn
- $62.58bn
US FDA approves updated COVID vaccines for 2026-27 season
China's drug regulator accepts Novo Nordisk's application for oral Wegovy (updated)
Focus: Snoring, subways and stealth ads: how big pharma targets China's waistline
Arbutus climbs after unveiling buyback from Moderna settlement proceeds
Factbox: Pharma sector doubles down on AI amid hopes of slashing costs, timelines
Biotech stocks hit record high after Moderna, Merck's melanoma vaccine trial win
Biotech stocks jump after Moderna, Merck's melanoma vaccine succeeds in large trial
GE HealthCare appoints William Grogan as CFO, replacing Jay Saccaro
Valneva surges after EU regulator validates Lyme disease vaccine application
Brief: Pfizer And Valneva's Lyme Disease Vaccine Candidate Marketing Authorization Application Validated By European Medicines Agency
Valneva falls after H1 revenue, operating profit drop
Factbox: Global drugmakers invest billions to boost US presence
Factbox: Global drugmakers invest billions to boost US presence
Bristol Myers to build $2.3 billion manufacturing site in Houston
Street View: Growth drugs lift Pfizer outlook, but execution remains key
U.S. STOCKS ON THE MOVE -Expeditors International, Waters, Ameresco
U.S. STOCKS ON THE MOVE-Expeditors International, Waters, Wayfair
Brief: Pfizer Says Net Cost Savings From Now Expected To Reach $6.7 Billion Through 2029
Pfizer Inc reports results for the quarter ended June 30 - Earnings Summary